South Korea Pulmonary Embolism Therapeutics Market Size & Outlook, 2026-2034

South Korea Pulmonary Embolism Therapeutics Market Insights

As per Reed Intelligence insights, the South Korea Pulmonary Embolism Therapeutics Market stood at USD 28.8 Million in 2025 and is anticipated to grow to USD 62.98 Million by 2034.
The South Korea market is expected to advance at a CAGR of 8.91% from 2026 through 2034.
In 2025, Anticoagulants accounted for the highest share of the Drug Class market size.
During the forecast period, Anticoagulants is set to register the highest growth, making it the most lucrative Drug Class segment.

Other Key Findings

In 2025, South Korea represented 0.76% of the overall global Pulmonary Embolism Therapeutics Market size.
United States is projected to lead the global Pulmonary Embolism Therapeutics Market size by 2034.
Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
Japan is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 192.99 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 28.8 Million
Market Size In 2034	USD 62.98 Million
Largest segment	Anticoagulants
Units	Revenue in USD Million
CAGR	8.91% (2026-2034)
Segmnetation Covered
Drug Class	Anticoagulants Thrombolytics Others
Route of Administration	Oral Injectable
End-Use	Hospitals Ambulatory Surgical Centers Specialty Clinics
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

South Korea Pulmonary Embolism Therapeutics Market Drug Class 2026-2034 (USD Million)

Drug Class	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Anticoagulants	XX.x	XX.x	XX.x	14.67	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Thrombolytics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

South Korea Pulmonary Embolism Therapeutics Market Route of Administration 2026-2034 (USD Million)

Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oral	XX.x	XX.x	XX.x	18.38	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Injectable	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

South Korea Pulmonary Embolism Therapeutics Market End-Use 2026-2034 (USD Million)

End-Use	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	13.53	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ambulatory Surgical Centers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.